- Oops!Something went wrong.Please try again later.
GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:
H.C. Wainwright 4th Annual NASH Investor Conference
Monday, October 5, 2020 – 3:30 pm ET
Guggenheim Securities’ 1st Annual Vaccines & Infectious Diseases Day
Monday, October 5, 2020 – 4:45 pm ET
The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events/Presentations.
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.
Ashley R. Robinson
Altimmune, Investor Relations
LifeSci Advisors, LLC